Description

PharmaQo Caber 1 provides 1 mg Cabergoline per oral tablet, packaged in 10-tablet packs for research use. Cabergoline is a dopamine agonist under investigation for its ability to reduce prolactin levels, modulate pituitary function, and influence endocrine and reproductive hormone pathways.

It is commonly used in research related to hyperprolactinemia, prolactinomas, sexual function studies, and hormone regulation models.

Product Details:
Active Ingredient:

• Cabergoline

Concentration: 1 mg per tablet

Form: Oral tablets

Packaging: 10 tablets per pack

Pharmacokinetics:
Cabergoline has a half-life of ~63–69 hours, allowing for twice-weekly dosing in research protocols.

Usage Recommendations:

• Indications (Research Context): Investigational use in prolactin suppression, pituitary research, endocrine modulation (not approved for human use)

• Typical Dosage (Research Use): 0.25–1 mg twice per week, depending on study

• Monitoring: Blood pressure, heart function, prolactin levels, pituitary hormone profiles

• Cycle/Duration: As determined by research design

Disclaimer:
This product is intended strictly for research and educational purposes. It is not for human consumption or therapeutic use. Not suitable for individuals under 18, pregnant or breastfeeding women, or those with cardiovascular or other medical risks. Always comply with local research laws and ethical standards.